Dystonia

FDA approves Medtronic Percept™ RC neurostimulator with exclusive BrainSense™ technology

Retrieved on: 
Monday, January 8, 2024
Patient, University, Essential tremor, Food, Parkinson's disease, Movement, Software, Epilepsy, FDA, Deep brain stimulation, CE marking, Neuroscience, Freedom, RC, Medtronic, Neurology, DBS, FAAN, Dystonia, Neuromodulation, DSM-IV codes, Medical imaging

DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system. The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology†, and SenSight™ directional leads. The Percept™ family is the only sensing-enabled DBS system on the market, allowing the physician to personalize treatment for patients with movement disorders such as Parkinson's disease, essential tremor, and dystonia* as well as epilepsy. Over 11 million people in the U.S. are living with movement disorders1-2 and approximately 3.4 million with epilepsy3.

Key Points: 
  • DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system.
  • The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology†, and SenSight™ directional leads.
  • Percept™ RC is available immediately throughout the U.S., as well as via CE Mark approval in Europe and availability in Japan.
  • For further information on the Percept™ neurostimulators with exclusive BrainSense™ technology, visit our website here .

Human medicines European public assessment report (EPAR): Cufence, trientine dihydrochloride, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Copper, Urine, Liver, Medical Subject Headings, Diarrhea, Marketing, Meal, Duodenitis, Roger Hawkins (drummer), DSM-IV codes, INN, Deficit spending, Metabolism, Stomach, ATC, Pain, Capsule, International, Tremor, Dysarthria, Ageing, Nausea, Language, Brain, Inflammation, Duodenum, European Medicines Agency, Wilson's disease, Dystonia, Select, Patient, Liver disease, Safety, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Cufence, trientine dihydrochloride, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Cufence, trientine dihydrochloride, Date of authorisation: 25/07/2019, Revision: 6, Status: Authorised

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Retrieved on: 
Friday, December 1, 2023
Quality of life, Protein, GLB1, GM1, Disorder, PLOS, Brain, Muscle weakness, Doctor of Philosophy, Research, Therapy, Glycogen storage disease, Life expectancy, DSM-IV codes, Paratriathlon, Dystonia, Protein folding, Patient, HaloTag, Pharmaceutical industry

BETHESDA, Md., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators that demonstrate therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage disorders (LSDs), including GM1 gangliosidosis. The study, “Validation of a highly sensitive HaloTag-based assay to evaluate the potency of a novel class of allosteric β-Galactosidase correctors,” was published in PLOS ONE.

Key Points: 
  • The study, “Validation of a highly sensitive HaloTag-based assay to evaluate the potency of a novel class of allosteric β-Galactosidase correctors,” was published in PLOS ONE.
  • GM1-gangliosidosis is an inherited, progressive disorder characterized by the degeneration of brain and spinal cord cells, leading to muscle weakness, skeletal abnormalities, dystonia, and vision problems.
  • Mutations in the GLB1 gene significantly reduce the activity and function of the lysosomal hydrolase enzyme β-galactosidase (β-Gal) due to protein misfolding.
  • Additionally, there are no available disease-modifying treatments for GM1 gangliosidosis, with available therapies only focused on reducing symptoms and improving quality of life.

Neurostimulation Technology and Global Markets Report 2023: 2020-2022 Data, Estimates for 2023, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 20, 2023
Medical Devices, Health, Quality of life, Obstructive sleep apnea, Essential tremor, DSM-IV codes, Epilepsy, Tremor, Chronic pain, Neuron, Brain, System, Projection, Spinal cord stimulator, Tic disorder, Incontinence, Parkinson's disease, Obesity, Tinnitus, Nervous system, Deep brain stimulation, Vagus nerve stimulation, Dystonia, Growth, Transcranial magnetic stimulation, Medical device

This report provides a comprehensive study of the global market for neurostimulation technologies and devices.

Key Points: 
  • This report provides a comprehensive study of the global market for neurostimulation technologies and devices.
  • It provides a detailed description of the different types of neurostimulation technologies and devices (invasive and noninvasive) and their current and historical market revenues.
  • Currently, the potential of neurostimulation technology is actively being explored for other clinical conditions including obesity, tinnitus and central nerve system disorders.
  • An in-depth analysis of the global market for neurostimulation technologies and devices includes historical data and market projections by device type, therapeutic application and region.

Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Display resolution, Dystonia, NYSE, DNA, GMP, Hope, Entrepreneurship, Tecmar, Degenerative disease, CDMO, Patient, Hereditary spastic paraplegia, Visual impairment, Genetic testing, Muscle weakness, Spasticity, Golden, Seizure, Cerebellar ataxia, Partnership, CRL, Doctor of Philosophy, Parent, HQ, Life, DSM-IV codes, Intellectual disability, Pharmaceutical industry, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures for rare diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures for rare diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio to simplify complex supply chains and meet growing demand for plasmid DNA, viral vector, and cell therapy services.
  • Combined with the Company’s legacy testing capabilities, Charles River offers a comprehensive “concept-to-cure” advanced therapies solution.
  • - Golden Whitrod, Tallulah Moon’s mother and Co-Founder and President, Genetic Cures for Kids, Inc.

North America Leads the CBD Boom as the Largest Market, Fueled by Favorable Regulatory Changes and Investments in Medicinal CBD Research - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 12, 2023
Cannabis, Natural Resources, Cream, Market, Yoga, Investment, Health, COVID-19, Timeline of cannabis laws in the United States, THC, Pharmacy, Anxiety, Lead, Research, Distribution, Crohn's disease, Epilepsy, Pain management, Cancer, Nausea, Education, DSM-IV codes, Seizure, Oil, Marketing, Dystonia, Depression, Chronic pain, Alzheimer's disease, Skin, Spasm, Social media, Arthritis, Conditional sentence, Argyreia nervosa, Parkinson's disease, Pharmaceutical industry, Dietary supplement, Drug, Cannabidiol, Capsule, Tablet, CBD

The global CBD (Cannabidiol) market is on a trajectory of substantial growth, with a projected value of US$6.17 billion by 2023.

Key Points: 
  • The global CBD (Cannabidiol) market is on a trajectory of substantial growth, with a projected value of US$6.17 billion by 2023.
  • The versatility of CBD is evident in its various forms, such as pills, patches, oils, extracts, vape pens, and topical skin treatments.
  • The global CBD market encompasses four regions: North America, Europe, Asia Pacific, and the Rest of the World.
  • Additionally, the presence of major market players further fuels growth, alongside increasing investments and favorable government initiatives.

Unlocking the Potential: Global Dystonia Drugs Market Set to Grow at 5.3% CAGR by 2027 - Analyzing Emerging Markets and Healthcare Advancements - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 27, 2023
Health, Pharmaceutical, Growth, Torticollis, Pharmacist, Dystonia, Drug, Research, Pharmacy, GABAergic, Pharmaceutical industry

Among these, GABAergic agents have the largest market share, attributed to their effectiveness in treating dystonia, especially cervical dystonia.

Key Points: 
  • Among these, GABAergic agents have the largest market share, attributed to their effectiveness in treating dystonia, especially cervical dystonia.
  • The pharmaceutical industry's discovery of highly effective GABAergic agent medications for dystonia treatment is further driving the growth of this segment.
  • The injectable segment holds a significant market share due to innovations in parenteral dosing and increased research and development for botulinum injections.
  • The drug stores and retail pharmacies segment dominates the market, benefiting from its extensive distribution network and longstanding presence as a convenient channel for drug distribution.

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

Retrieved on: 
Tuesday, August 1, 2023
Patent, Extremities, CSE, Central nervous system, Therapy, Tic disorder, Face, United States Patent and Trademark Office, DSM-IV codes, Tourette syndrome, Dystonia, FSE, IP, TEL, Disorder, Parkinson's disease, CWY, Chorea, Pharmaceutical industry, Dyskinesia

The provisional patent application was filed with the United States Patent and Trademark Office.

Key Points: 
  • The provisional patent application was filed with the United States Patent and Trademark Office.
  • This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc's Palmitoylethanolamide as a potential treatment for dyskinesia.
  • This patent prospect corresponds well with SciSparc’s robust IP portfolio and some of the indications the Company is already pursuing such as Tourette Syndrome.
  • Our collaboration with Clearmind continues to bear fruit and emphasizes our commitment to pioneering innovative treatments for conditions with unmet need,” stated SciSparc’s Chief Executive Officer, Oz Adler.

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Retrieved on: 
Tuesday, August 1, 2023
Patent, Extremities, CSE, Obesity, Therapy, Face, United States Patent and Trademark Office, DSM-IV codes, MEAI, Dystonia, FSE, Disorder, Parkinson's disease, Patient, CWY, Myenteric plexus, Chorea, Pharmaceutical industry, Dyskinesia

The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.

Key Points: 
  • The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.
  • "Clearmind continues to strengthen its position as a leader in the psychedelic-derived therapeutics industry through an aggressive strategy to expand our IP portfolio.
  • Clearmind has a broad IP footprint in the psychedelic space with 30 patents and patent applications across 14 patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India.
  • The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's Palmitoylethanolamide for treating alcohol use disorder, cocaine addiction, and obesity, as well as related metabolic disorders.

UT Health Science Center San Antonio recognized as Parkinson's Foundation Comprehensive Care Center

Retrieved on: 
Tuesday, August 1, 2023
Workforce, Huntington's disease, Deep brain stimulation, Hallucination, University, Center of excellence, Tic, Parkinson's Foundation, University of Texas System, University of Texas Health Science Center at San Antonio, Senior counsel, DSM-IV codes, Therapy, Health, Parkinson's disease dementia, Quality of life, UT Health San Antonio Cancer Center, Research, Brain, Neurology, Department of Neurology, Xuanwu hospital, Dystonia, Bone, Movement, Teaching hospital, Essential tremor, Pain, Social, DBS, Electrode, Parkinson's disease, Neurosurgery, MD, Patient, SAN, Person-centered therapy, Rush Alzheimer's Disease Center, Long School, Long School of Medicine, Movement disorder, Bleeding, Memory, Skin, Disease, Pharmaceutical industry, Nursing, Veterinary medicine, Dentistry, Central Texas

SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.

Key Points: 
  • Advanced multidisciplinary care for Parkinson's disease is available at The University of Texas Health Science Center at San Antonio, which this summer was named a Parkinson's Foundation Comprehensive Care Center.
  • SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.
  • The UT Health San Antonio Movement Disorders Center is also recognized as a Huntington's Disease Center of Excellence and provides comprehensive care for patients with Huntington's disease.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver for San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of more than $360 million.